Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1semaglutideperipheral artery diseasecardiovascularglp-1

Commentary weighs semaglutide's effect on limb events in cardiovascular prevention

European Journal of Preventive Cardiology authors ask whether peripheral limb outcomes expand the drug's prevention role.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 20:00 ETSource: European journal of preventive cardiology

The wire

  1. 01A commentary examined semaglutide and limb events within cardiovascular prevention frameworks.
  2. 02Peripheral artery outcomes could broaden how clinicians position GLP-1 therapy in vascular care.
  3. 03The piece is editorial; underlying trial data and magnitude of benefit are not given in the excerpt.

From the source

Semaglutide and Limb Events: Expanding the Cardiovascular Prevention Paradigm?

European journal of preventive cardiology · 2026 Sep 17 · Canonico ME, Bonaca MP et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42751734/